The leading reasons for non-adherence were: economy (35, 2%) and good response (31, 8%), the Covid-19 pandemic (17, 6%); of dose dilatation were good response (66, 3%), economy (12, 8%), the Covid-19 pandemic (12, 2%) and out of drugs (1, 6%); the causes of drug discontinuation were largely due to economic reasons accounting for 50% and other reasons: Side effects (14, 3%), the Covid-19 pandemic (12, 2%) and the causes of changing biological drugs were primary nonresponsive (24%) secondary nonresponsive (34%) and side effects (20%).